Search

everythinglearnresearchcommunity

for

Search:↓

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

The combination therapy improved PCOS symptoms in both obese and non-obese women, with weight loss in the obese group.

Most doctors know the thrombosis risk with Cyproterone/Ethinylestradiol, but some lack details on less common risks and patient instructions; educational materials are underused but useful.

Mood stabilizers like lithium and anticonvulsants have side effects that can lead to patients stopping their medication, and managing these effects is important for treatment adherence.

Some birth control pills increase blood clot risk; use them for specific conditions only.

Careful management of blood thinners is crucial for lupus patients with APS.

New drug uses show promise but need more research.

GLP-1RA therapy may increase the risk of hair loss.

Properly administered testosterone therapy is safe and effective but often not covered by insurance.

Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.

Different PCOS characteristics affect lipid profiles, increasing cardiovascular disease risk, so regular lipid screening is advised.

Evening primrose oil significantly improves hormone levels and reduces BMI and cholesterol in women with PCOS.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Dietary linoleic acid may help reduce hyperthyroidism effects.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Patients with oral lichen planus or oral lichenoid reactions had worse cholesterol levels and a higher risk of obesity compared to healthy individuals.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

In 2001, the FDA approved 12 new drugs for children to treat allergies, asthma, ADHD, birth control, and other conditions.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Golvatinib shows promise as a treatment for Omicron in elderly patients.

Lamotrigine may cause hair loss, affecting treatment compliance and health.

Metformin lowers prolactin in men with normal hair but not in those with early hair loss.

Finasteride is more stable in sunlight than Diclofenac and Naproxen.

Strontium ranelate is no longer available for treatment.

The PON1 192R gene variant is linked to a higher risk of psoriasis and heart disease in Western Mexico.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.